We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to treat B-cell lymphomas; however...
The U.S. Food and Drug Administration approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.